Ligand Pharmaceuticals (LGND) Current Deferred Revenue (2010 - 2025)
Ligand Pharmaceuticals (LGND) posted Current Deferred Revenue of $111000.0 for Q2 2025, up 9.9% sequentially from $101000.0 in Q1 2025, and down 90.72% YoY from $1.2 million in Q2 2024.
Ligand Pharmaceuticals (LGND) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Ligand Pharmaceuticals has reported Current Deferred Revenue for 14 years, with the latest figure at $111000.0 in Q2 2025.
- Quarterly Current Deferred Revenue fell 90.72% year-over-year to $111000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $111000.0 (down 90.72% YoY) and the FY2024 annual result came in at $1.3 million, up 4.58% from the prior year.
- Current Deferred Revenue rose to $111000.0 in Q2 2025 per LGND's latest filing, from $101000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $25.1 million in Q1 2021 and troughed at $101000.0 in Q1 2025.
- A 5-year average of $5.8 million and a median of $1.2 million in 2023 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 476.64% in 2021, down 97.78% in 2021.
- Over 5 years, Current Deferred Revenue stood at $654000.0 in 2021, then sank by 45.72% to $355000.0 in 2022, then jumped by 244.23% to $1.2 million in 2023, then climbed by 4.58% to $1.3 million in 2024, then slumped by 91.31% to $111000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $111000.0, $101000.0, and $1.3 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Mar 31, 2023 | 257,000.00 |
| Dec 31, 2022 | 355,000.00 |
| Sep 30, 2022 | 9.55 Mn |
| Jun 30, 2022 | 10.58 Mn |
| Mar 31, 2022 | 10.50 Mn |
| Dec 31, 2021 | 654,000.00 |
| Sep 30, 2021 | 12.01 Mn |
| Jun 30, 2021 | 17.15 Mn |
| Mar 31, 2021 | 25.11 Mn |
| Dec 31, 2020 | 29.44 Mn |
| Sep 30, 2020 | 5.40 Mn |
| Jun 30, 2020 | 8.92 Mn |
| Mar 31, 2020 | 4.35 Mn |